EFMC-ISMC 2021
Conferences > Archives > EFMC-ISMC 2021

Confirmed Speakers


EFMC Award Lectures

Prof. Ad P. IJZERMAN
Prof. Ad P. IJZERMAN
LEIDEN UNIVERSITY, Leiden, The Netherlands
Read more

The Nauta Pharmacochemistry Award for Medicinal Chemistry and Chemical Biology
Award Lecture
Partial Agonism in the Picture (AL001)

Dr Malin LEMURELL
Dr Malin LEMURELL
ASTRAZENECA, Gothenburg, Sweden
Read more

The UCB-Ehrlich Award for Excellence in Medicinal Chemistry
Award Lecture
Experiences & Future Direction for Medicinal Chemistry in Cardiovascular, Renal and Metabolism Diseases (AL002)

Prof. Gisbert SCHNEIDER
Prof. Gisbert SCHNEIDER
ETH ZÜRICH, Zürich, Switzerland

The Prous Institute - Overton and Meyer Award for New technologies in Drug Discovery
Award Lecture
De Novo Drug Design with Machine Intelligence (AL003)

Prize Lectures

Dr Niall ANDERSON
Dr Niall ANDERSON
GLAXOSMITHKLINE, Hertfordshire, United Kingdom
Read more

The 2021 EFMC Prize for a Young Medicinal Chemist in Industry
Integrin Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis (PR003)

Prof. Yimon AYE
Prof. Yimon AYE
EPFL, Lausanne, Switzerland

Read more

The 2020 EFMC Prize for a Young Medicinal Chemist in Academia
Within Our Control? Illuminating How Ephemeral Electrophiles Rewire Cell Decision-Making Processes (PR002)

Dr Giuseppe CECERE
Dr Giuseppe CECERE
F. HOFFMANN-LA ROCHE, Basel, Switzerland
Read more

The 2020 EFMC Prize for a Young Medicinal Chemist in Industry
Discovery of Potent Selective GABAA Alpha5 Positive Allosteric Modulators (PAMs) for the treatment of neurological disorders (PR001)

Dr Nir LONDON
Dr Nir LONDON
THE WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel
Read more

The 2021 EFMC Prize for a Young Medicinal Chemist in Academia
COVID Moonshot – Crowdsourcing a Covid-19 Cure (PR004)

Dr John E. MACOR
Dr John E. MACOR
SANOFI, Waltham, United States
Read more

The IUPAC-Richter Prize Lecture
The Discovery of Relpax® and Nurtec ODT® - Two Different Treatments for Migraine Headaches (PR005)

Prof. Stephan A. SIEBER
Prof. Stephan A. SIEBER
TECHNICAL UNIVERSITY MUNICH, Garching, Germany

Read more

The Klaus Grohe Award Lecture
Chemical-Proteomic Strategies to Fight Multiresistant Bacteria (AL004)

Plenary Lectures

Prof. Phil BARAN
Prof. Phil BARAN
THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States

Read more

Translational Chemistry (PL003)

Dr Karin BRINER
Dr Karin BRINER
NOVARTIS, Cambridge, United States
Read more

Opening Lecture
Creating the Next Generation of Therapeutics - Medicinal Chemistry Unleashed (PL001)

Dr Jean-Paul CLOZEL
Dr Jean-Paul CLOZEL
IDORSIA PHARMACEUTICALS LTD, Allschwil, Switzerland
Read more

Medicinal Chemistry: More than Ever (PL002)

Prof. Stefan KNAPP
Prof. Stefan KNAPP
GOETHE UNIVERSITY FRANKFURT, Frankfurt am Main, Germany
Read more

Targeting Protein Scaffolding Function in Kinases (PL004)

Invited Speakers

Dr Stellios ARSENIYADIS
Dr Stellios ARSENIYADIS
QUEEN MARY UNIVERSITY OF LONDON, London, United Kingdom
Read more

Innovative DNA-based Asymmetric Catalysis (LE033)

Prof. Andreas BENDER
Prof. Andreas BENDER
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
Read more

Artificial Intelligence in Chemical Biology and Drug Discovery - Data, Applications, and Illusions (LE059)

Prof. Gonçalo BERNARDES
Prof. Gonçalo BERNARDES
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom

Read more

Translational Chemical Biology (LE001)

Prof. Erem BILENSOY
Prof. Erem BILENSOY
HACETTEPE UNIVERSITY, Ankara, Turkey
Read more

Omics-Based Development of Nanomedicines for Safe and Effective Drug Delivery in Cancer (LE077)

Prof. Rebecca BULLER
Prof. Rebecca BULLER
ZHAW SCHOOL OF LIFE SCIENCES AND FACILITY MANAGEMENT, Wädenswil, Switzerland
Read more

Utilization of Fe/α-Ketoglutarate-Dependent Enzymes for Stereocontrolled Functionalization (LE098)

Prof. Erick M. CARREIRA
Prof. Erick M. CARREIRA
ETH ZÜRICH, Zürich, Switzerland

Read more

Recent Developments in Strategies and Tactics Towards Complex Secondary Metabolites (LE032)

Dr Paola CASTALDI
Dr Paola CASTALDI
LIFEMINE THERAPEUTICS, Cambridge, United States
Read more

Mechanistic Insights of a CDK9 Inhibitor via Orthogonal Proteomics Methods (LE092)

Dr Grace CHUANG
Dr Grace CHUANG
CYTOKINETICS, South San Francisco, United States
Read more

Discovery of Aficamten (CK-274): A Novel, Small Molecule, Cardiac Myosin Inhibitor for the Potential Treatment of Hypertrophic Cardiomyopathies (HCM) (LE022)

Prof. Bernd CLEMENT
Prof. Bernd CLEMENT
UNIVERSITY OF KIEL, Kiel, Germany
Read more

New Examples for N-Hydroxyamidine Prodrugs (LE085)

Prof. Leroy CRONIN
Prof. Leroy CRONIN
UNIVERSITY OF GLASGOW, Glasgow, United Kingdom
Read more

Universal Synthesis Machines and Chemputation (LE045)

Dr Eva CUNHA
Dr Eva CUNHA
UNIVERSITY OF OSLO & OSLO UNIVERSITY HOSPITAL, OSLO, Norway
Read more

Structure Based Drug Discovery Targeting Helicobacter Pylori, Using Cryo-EM (LE020)

Dr Werngard CZECHTIZKY
Dr Werngard CZECHTIZKY
ASTRAZENECA, Mölndal, Sweden
Read more

Inhaled New Modalities in Respiratory Disease: Past, Present, Future (LE048)

Dr Mike DAWSON
Dr Mike DAWSON
MIKE DAWSON ANTIMICROBIAL RESEARCH CONSULTANCY LTD., Stevenage, United Kingdom
Read more

Therapies for Gram-Negative Bacterial Infections: New Approaches and Further Generations of Existing Series (LE063)

Dr Sheng DING
Dr Sheng DING
UNIVERSITY OF CALIFORNIA SAN FRANCISCO, San Francisco, United States

Read more

A Chemical Approach to Controlling Cell Fate (LE040)

Prof. Joerg DISTLER
Prof. Joerg DISTLER
UNIVERSITY OF ERLANGEN–NUREMBERG, Erlangen, Germany
Read more

Novel Molecular Targets for the Treatment of Fibrosis (LE088)

Dr Ola ENGKVIST
Dr Ola ENGKVIST
ASTRAZENECA, Mölndal, Sweden
Read more

Progress and Limitations in Exploring the Chemical Space with AI (LE047)

Dr Montse ERRA SOLA
Dr Montse ERRA SOLA
ALMIRALL, S.A., Barcelona, Spain
Read more

Discovery of Novel Inhaled PI3Kd Inhibitor by Lung Retention Optimisation (LE049)

Dr Niyi FADEYI
Dr Niyi FADEYI
MERCK & CO, Cambridge, United States
Read more

Mapping Cell-Cell Interactions in Tumor Microenvironment via Photocatalytic Proximity Labeling (LE014)

Dr Romain GOSMINI
Dr Romain GOSMINI
GALAPAGOS, Romainville, France
Read more

Discovery of GLPG1205, a First in Class GPR84 Antagonist in Phase II Clinical Trial (LE089)

Dr David HARDICK
Dr David HARDICK
STORM THERAPEUTICS LTD, Cambridge, United Kingdom
Read more

Drugging RNA Modifying Enzymes - METTL3 Inhibitors (LE068)

Prof. Amanda HARGROVE
Prof. Amanda HARGROVE
DUKE UNIVERSITY, Durham, United States
Read more

Modulating Viral RNAS with Amiloride Small Molecules (LE070)

Dr Gerhard HESSLER
Dr Gerhard HESSLER
SANOFI-AVENTIS DEUTSCHLAND, Frankfurt am Main, Germany
Read more

Navigating Chemical Space by Artificial Intelligence (LE061)

Prof. Donald HILVERT
Prof. Donald HILVERT
ETH ZURICH, ZURICH, Switzerland
Read more

Reprogramming Nonribosomal Peptide Biosynthesis (LE096)

Dr Kristiina HUTTUNEN
Dr Kristiina HUTTUNEN
UNIVERSITY OF EASTERN FINLAND, Kuopio, Finland
Read more

Targeted (Pro)Drugs for Improved Treatment of Brain Tumors (LE087)

Dr Anne IMBERTY
Dr Anne IMBERTY
CNRS/CERMAV, Grenoble, France
Read more

Lectins from Pathogens: From Structural Glycobiology to Antiadhesive Strategies (LE057)

Prof. Klavs F. JENSEN
Prof. Klavs F. JENSEN
MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, United States
Read more

AI Assisted and Automated Chemical Synthesis (LE044)

Dr Tim JONCKERS
Dr Tim JONCKERS
JANSSEN, Beerse, Belgium
Read more

Discovery of a Novel Class of Small Molecule Dengue Virus Inhibitors (LE036)

Dr Markus KLEIN
Dr Markus KLEIN
MERCK KGAA, Darmstadt, Germany
Read more

Structure-Based Optimization and Synthesis of M3258, a Potent and Selective Inhibitor of the Immunoproteasome Subunit LMP7 (beta5i) Demonstrating Strong Efficacy in Multiple Myeloma Models (LE101)

Dr Teodoro LAINO
Dr Teodoro LAINO
IBM RESEARCH EUROPE, Rueschlikon, Switzerland
Read more

AI in the Lab: Automating Chemical Synthesis. Where Next From Here? (LE046)

Dr Sergio MALLART
Dr Sergio MALLART
SANOFI R&D, CHILLY MAZARIN, France
Read more

Identification of Potent and Long Acting Single-Chain Peptide Mimetics of Human Relaxin-2 for Cardiovascular Diseases (LE021)

Dr Muthiah MANOHARAN
Dr Muthiah MANOHARAN
ALNYLAM PHARMACEUTICALS, Cambridge, United States
Read more

Nucleic Acids as Household Medicine: Living in The World of RNA Therapeutics (LE076)

Dr Patrizio MATTEI
Dr Patrizio MATTEI
ROCHE INNOVATION CENTER BASEL, Basel, Switzerland
Read more

Tethered Macrocyclic Peptides, a Novel Antibiotic Class Targeting Acinetobacter Baumannii (LE064)

Dr Daniel MEIBOM
Dr Daniel MEIBOM
BAYER PHARMA, Wuppertal, Germany
Read more

Neladenoson Bialanate Hydrochloride: a Prodrug Exploration of a Partial Adenosine A1 Agonist (LE086)

Prof. Marko D. MIHOVILOVIC
Prof. Marko D. MIHOVILOVIC
TU WIEN, Vienna, Austria
Read more

Flavoenzyme Biocatalysis in Bioorganic and Medicinal Chemistry - Challenges and Opportunities (LE097)

Prof. Barbara MONTI
Prof. Barbara MONTI
UNIVERSITY OF BOLOGNA, Bologna, Italy
Read more

Microglia in Neuroinflammation: an Intriguing Target towards Neuroprotection and Neuroregeneration (LE009)

Dr Herbert NAR
Dr Herbert NAR
BOEHRINGER INGELHEIM, Biberach, Germany
Read more

Allosteric Regulation of GTP Cyclohydrolase I (LE018)

Prof. Dario NERI
Prof. Dario NERI
ETH ZÜRICH, Zürich, Switzerland
Read more

Antibody-Drug Conjugates (ADC) and Small Molecule-Drug Conjugates (SMDC): a Comparative Evaluation (LE075)

Dr Gary NEWTON
Dr Gary NEWTON
THE INSTITUTE OF CANCER RESEARCH, London , United Kingdom
Read more

MAP4K4 Inhibitors For The Suppression Of Cardiac Muscle Cell Death (LE023)

Prof. Ulf NILSSON
Prof. Ulf NILSSON
LUND UNIVERSITY, Lund, Sweden
Read more

Design, Synthesis, and Development of Lectin Ligand Mimetics (LE056)

Dr Valle PALOMO
Dr Valle PALOMO
CENTRO DE INVESTIGACIONES BIOLÓGICAS-CSIC, Madrid, Spain
Read more

Sensing Enzymatic Activity with Quantum Dots in Patient-Derived Neurodegenerative Disease Models (LE003)

Prof. Maria-Jesus PÉREZ-PÉREZ
Prof. Maria-Jesus PÉREZ-PÉREZ
INSTITUTO DE QUÍMICA MÉDICA, Madrid, Spain
Read more

Antivirals Against Chikungunya Virus: Analyzing the Current Situation to Identify New Opportunities (LE037)

Dr Jennifer PETTER
Dr Jennifer PETTER
ARRAKIS THERAPEUTICS, Waltham, United States
Read more

Targeting RNA With Drug-Like Small Molecules (LE067)


Dr Jonathan PHILLIPS
AMGEN, Newbury Park, United States

Introduction to Preclinical Inhaled Drug Dosing and its Application to Measure the Therapeutic Index of Inhaled Steroids (LE050)

Prof. Paola PICOTTI
Prof. Paola PICOTTI
ETH ZÜRICH, Zürich, Switzerland
Read more

Proteomes in 3D (LE093)

Prof. Tracey PIRALI
Prof. Tracey PIRALI
UNIVERSITÀ DEL PIEMONTE ORIENTALE, Novara, Italy
Read more

Magic in the Moonlight: Our Contribution to the Development of IDO1 Inhibitors for Cancer Immunotherapy (LE102)

Prof. Colin POUTON
Prof. Colin POUTON
MONASH UNIVERSITY, Clayton, Australia
Read more

Potential of Stem Cell Technology in Discovery of Drugs for Neurodegenerative Diseases (LE043)


Dr Xiangbing QI
TSINGHUA UNIVERSITY | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCE, China

Molecular Glue Design for Targeted Cancer Therapy (LE006)

Dr Christoph RADEMACHER
Dr Christoph RADEMACHER
UNIVERSITY OF VIENNA, Vienna, Austria
Read more

C-type Lectin Receptors as Drug Targets (LE055)

Prof. Daniel RAUH
Prof. Daniel RAUH
TU DORTMUND, Dortmund, Germany
Read more

Targeting Cancer (LE100)

Prof. Jarkko RAUTIO
Prof. Jarkko RAUTIO
UNIVERSITY OF EASTERN FINLAND, Kuopio, Finland
Read more

Prodrug Strategies in Medicinal Chemistry (LE084)

Dr Judith REEKS
Dr Judith REEKS
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom
Read more

The Role of Cryo-EM in Fragment-Based Drug Discovery (LE019)

Prof. Pablo RIVERA FUENTES
Prof. Pablo RIVERA FUENTES
EPF LAUSANNE, Lausanne, Switzerland
Read more

Chemical Tools to Study Redox Biology (LE002)

Prof. Angela RUSSELL
Prof. Angela RUSSELL
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Read more

Discovery of Small Molecules to Manipulate Cell Fate in vivo: Towards New Therapies for Degenerative Diseases (LE041)

Dr Nadine SCHNEIDER
Dr Nadine SCHNEIDER
NOVARTIS, Basel, Switzerland
Read more

Augmenting Drug Hunters with Generative Chemistry Models (LE060)

Dr Stacey SOUTHALL
Dr Stacey SOUTHALL
SOSEI HEPTARES, Cambridge, United Kingdom
Read more

Cryo-EM in GPCR Structure Based Drug Discovery (LE017)

Dr Wiktor SZYMANSKI
Dr Wiktor SZYMANSKI
UNIVERSITY OF GRONINGEN, Groningen, The Netherlands
Read more

Photopharmacology: Towards Light-Controlled Therapy (LE013)

Dr Thomas THUM
Dr Thomas THUM
HANNOVER MEDICAL SCHOOL (MHH), Hannover, Germany

Read more

Development of Non-Coding RNA Based Next-Generation Heart Failure Therapeutics (LE024)

Dr Mario VAN DER STELT
Dr Mario VAN DER STELT
LEIDEN UNIVERSITY, Leiden, The Netherlands
Read more

Chemical Probes to Study Lipid Signaling (LE029)

Prof. Jan VAN MAARSEVEEN
Prof. Jan VAN MAARSEVEEN
UNIVERSITY OF AMSTERDAM, Amsterdam, The Netherlands
Read more

Scaffold-Assisted Peptide Cyclizations: Towards Protein Mimics (LE034)

Prof. Paul WORKMAN
Prof. Paul WORKMAN
INSTITUTE OF CANCER RESEARCH, London, United Kingdom
Read more

Chemical Probes to Explore Cancer Biology and Validate Drug Targets (LE028)

Prof. Bernhard WÜNSCH
Prof. Bernhard WÜNSCH
UNIVERSITY OF MÜNSTER, Münster, Germany
Read more

Development of Fluorinated PET Tracers for Imaging of α1 Receptors in the Brain (LE010)

Prof. Shengyong YANG
Prof. Shengyong YANG
SICHUAN UNIVERSITY, Sichuan, China
Read more

Discovery of New SARS-COV-2 MPRO Inhibitors With Potent in vitro and In vivo Antiviral Activity (LE007)

Prof. Jian ZHANG
Prof. Jian ZHANG
SHANGHAI JIAO TONG UNIVERSITY, Shanghai, China
Read more

Along the Allostery Stream: Recent Advances in Computational Methods for Allosteric Drug Discovery (LE005)

First Time Disclosures

Dr Simona COTESTA
Dr Simona COTESTA
NOVARTIS, Basel, Switzerland
Read more

Discovery of JDQ443 a Structurally Unique, Highly Potent, Selective and Orally Bioavailable KRASG12C Covalent Inhibitor (LE054)

Mr Kevin DACK
Mr Kevin DACK
LEO PHARMA, Ballerup, Denmark
Read more

Discovery of an Oral, RO5 Compliant, Interleukin 17a Protein-Protein Interaction Modulator for the Treatment of Psoriasis and other Inflammatory Diseases (LE052)

Dr Thomas FUCHSS
Dr Thomas FUCHSS
MERCK KGAA, Darmstadt, Germany
Read more

Insights to the Discovery and Design of Ataxia Telangiectasia Mutated (ATM) Kinase inhibitors M3541 and M4076 with Strong Anti-tumor Efficacy in Combination Therapy Approaches (LE053)

Dr Jörg KLEY
Dr Jörg KLEY
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach an der Riss, Germany
Read more

First Time Disclosure of BI 1265162, an ENaC Inhibitor for the Treatment of Cystic Fibrosis (LE026)

Dr Magnus NILSSON
Dr Magnus NILSSON
ASTRAZENECA, Mölndal, Sweden
Read more

Discovery of the Clinical Candidate AZD4604, a Potent and Selective Janus Kinase 1 Inhibitor, as an Inhaled Treatment for Respiratory Disease (LE027)

Dr Susanne ROEHRIG
Dr Susanne ROEHRIG
BAYER HEALTHCARE, Wuppertal, Germany
Read more

Design and Preclinical Characterization Program Towards BAY 2433334, an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders (LE025)

Oral Communications


Prof. Carolina H. ANDRADE
FEDERAL UNIVERSITY OF GOIAS , Goiânia, Brazil
Read more

Artificial Intelligence for Emerging and Neglected Diseases Drug Discovery (LE038)

Dr Andrea ASTOLFI
Dr Andrea ASTOLFI
UNIVERSITY OF PERUGIA, Perugia, Italy
Read more

Small Molecule Degradeers Targeting Folding Intermediates: the Prion Protein Case Study (LE012)

Mr André CAMPANICO
Mr André CAMPANICO
I.MED.ULISBOA - FFULISBOA, Lisboa, Portugal
Read more

Azaaurones as Novel Chemotypes Against Mycobacterium Tuberculosis: SAR ADME Profiling and Photo-Switching Properties (LE015)

Ms Emma CAMPBELL
Ms Emma CAMPBELL
UNIVERSITY OF STRATHCLYDE, Glasgow, United Kingdom
Read more

Splice-Switching Small Molecules as Inducers of Apoptosis (LE069)

Ms Aline CARREL
Ms Aline CARREL
UNIVERSITY OF BERN, Bern, Switzerland
Read more

Synthesis of New Building Blocks from the Chemical Universe Database GDB (LE035)

Dr Pooja DESHMUKH
Dr Pooja DESHMUKH
SAI LIFESCIENCES PVT LIMITED, Hyderabad, India

Generative Recurrent Neural Networks (RNN) for de novo Drug Design (LE062)

Ms Radhia EL PHIL
Ms Radhia EL PHIL
UNIGE, Geneva , Switzerland
Read more

A Novel Bacterial Three-Hybrid System for Target Identification in Bacteria (LE094)

Ms Rita FÉLIX
Ms Rita FÉLIX
IMED.ULISBOA - INSTITUTO DE INVESTIGAÇÃO DO MEDICAMENTO, Lisboa, Portugal
Read more

Quenched Activity-based Probes as New Chemical Tools to Analyse Resistance to Antibiotics (LE031)

Dr Christian FISCHER
Dr Christian FISCHER
MERCK, SHARP & DOHME, Boston, United States
Read more

Discovery of MRK-740, a First-in-class, Potent, Selective and Cell Active PRDM9 Chemical Probe (LE030)

Dr Stefanie FLOHR
Dr Stefanie FLOHR
NOVARTIS, Basel, Switzerland
Read more

LNP023: Discovery and Synthesis of a First-In-Class, Oral Factor B Inhibitor for Treatment of Rare Renal and Hematological Diseases (LE074)

Prof. Evripidis GAVATHIOTIS
Prof. Evripidis GAVATHIOTIS
ALBERT EINSTEIN COLLEGE OF MEDICINE, New York, United States
Read more

Targeting Oncogenic BRAF Using a Novel Allosteric Site (LE072)

Dr Elena GOMEZ
Dr Elena GOMEZ
ALMIRALL, BARCELONA, Spain
Read more

Discovery of LAS200019, a Novel Topical Jak Inhibitor for the Treatment of Inflammatory Skin Diseases (LE083)

Mr Salvador GUARDIOLA
Mr Salvador GUARDIOLA
ONA THERAPEUTICS, Barcelona, Spain
Read more

Target-Templated de novo Design of Drug-like Cyclic Peptides: PD-1/PD-L1 Inhibitors (LE082)

Dr Rachel HEVEY
Dr Rachel HEVEY
UNIVERSITÄT BASEL, Basel, Switzerland
Read more

Development of Glycomimetic Collectin-11 Antagonists to Reduce Complement-Mediated Ischemia-Reperfusion Injuries (LE058)

Prof. Anna K. H. HIRSCH
Prof. Anna K. H. HIRSCH
HELMHOLTZ INSTITUTE FOR PHARMACEUTICAL RESEARCH SAARLAND, Saarbrücken, Germany
Read more

Discovery of Submicromolar Inhibitors of the Virulence Factor LASB from Pseudomonas Aeruginosa Using Rational Design (LE065)

Dr Laia JOSA CULLERE
Dr Laia JOSA CULLERE
INSTITUTE FOR ADVANCED CHEMISTRY OF CATALONIA (IQAC-CSIC), Barcelona, Spain
Read more

A Phenotypic Screen Identifies a Small Molecule that Induces Differentiation of AML Cells in vitro and Shows Anti-Tumour Effects in vivo (LE080)

Dr Tanya KELLEY
Dr Tanya KELLEY
UNIVERSITY OF MIAMI, Miami, United States
Read more

Design and Optimization of a First-in-class NACK Inhibitor: A Novel Path to Notch Inhibition (LE103)

Prof. Enza LACIVITA
Prof. Enza LACIVITA
UNIVERSITÀ DEGLI STUDI DI BARI, Bari, Italy
Read more

Boosting the Resolution of Inflammation Through Formyl Peptide Receptor 2 (FPR2) Agonists as a Novel Strategy in Neuroinflammation-associated Central Nervous System Disorders (LE011)

Prof. Stefan LAUFER
Prof. Stefan LAUFER
UNIVERSITY OF TÜBINGEN, Tübingen, Germany
Read more

Discovery and Development of a Mkk-4 Inhibitors to Increase Liver Regeneration (LE071)

Dr Marco LOLLI
Dr Marco LOLLI
UNIVERSITY OF TURIN, Torino, Italy
Read more

Innovative Dihydroorotate Dehydrogenase Clinical Ready Inhibitors as Pan-Coronavirus Antivirals: Targeting the Unexpected with Innovation (LE039)

Dr Laia MIRET CASALS
Dr Laia MIRET CASALS
GHENT UNIVERSITY, Gent, Belgium
Read more

Furan-Oxidation Mediated Technology: from in vitro Analysis of Protein-Protein Interactions to GPCR-Ligand Interactions on Live Cells (LE073)

Dr Leila MOTIEI
Dr Leila MOTIEI
WEIZMANN INSTITUTE OF SCIENCE, Rehovot, Israel
Read more

Pattern-generating Fluorescent Molecular Probes for Chemical Biology (LE004)

Ms Vanesa NOZAL GARCIA
Ms Vanesa NOZAL GARCIA
CIB - CSIC, Madrid, Spain
Read more

Isoform-selective TAU Tubuline Kinase 1 Inhibitors Reduce TDP-43 Hyperphosphorylation: a New Hope in the Treatment of TDP-43 Proteinopathies (LE081)

Dr Adeline PALISSE
Dr Adeline PALISSE
GALAPAGOS NV, Mechelen, Belgium
Read more

Discovery of the Highly Potent and Selective S1P2 Antagonist GLPG2938, a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis (LE091)

Prof. Sebastien PAPOT
Prof. Sebastien PAPOT
SCT & UNIVERSITY OF POITIERS, Poitiers, France
Read more

Targeting the Specificities of the Tumor Microenvironment for Cancer Therapy and Diagnosis (LE078)

Mr Carsten PEUKERT
Mr Carsten PEUKERT
HELMHOLTZ CENTRE FOR INFECTION RESEARCH, Braunschweig, Germany
Read more

DOTAM-based Sideromycins to Visualize and Treat MDR Bacterial Pathogens in vivo and in vitro (LE066)

Dr Davia PRISCHICH
Dr Davia PRISCHICH
INSTITUTE FOR BIOENGINEERING OF CATALONIA (IBEC) , Barcelona, Spain
Read more

In vivo Adrenergic Modulation with Photopharmacology (LE016)

Ms Jessica  REYNOLDS
Ms Jessica REYNOLDS
UNIVERSITY OF OXFORD, Oxford, United Kingdom
Read more

EFMC-YMCS Presentation Prize
Design and Synthesis of Chemical Tools to Probe the Function of TRIM33 (LE095)

Ms Suzanne Sherihan SAHRAOUI
Ms Suzanne Sherihan SAHRAOUI
UNIVERSITY OF GENEVA, Geneva, Switzerland
Read more

Development of A New Target Identification System for Small Molecules in Trypanosoma Brucei Parasites (LE008)

Prof. Dennis SCHADE
Prof. Dennis SCHADE
CHRISTIAN-ALBRECHTS-UNIVERSITY OF KIEL, Kiel, Germany
Read more

Probing Embryonic Mesodermal Differentiation Enables Identification of Small Molecule Bone Morphogenetic Protein Activators (LE042)

Mr Frank SCHEFFLER
Mr Frank SCHEFFLER
HYPHA DISCOVERY LTD, Abingdon, United Kingdom
Read more

Integration of Biocatalysis into Medicinal Chemistry Programs for Late-Stage Oxidised Derivatives using Polycyps Enzymes (LE099)

Dr Duncan SHAW
Dr Duncan SHAW
NOVARTIS, Cambridge, United States
Read more

Design and Development of Inhaled Molecules to Target the Pulmonary Vasculature (LE051)

Dr Julie SPICER
Dr Julie SPICER
THE UNIVERSITY OF AUCKLAND, Auckland, New Zealand
Read more

Toward a New Therapy for Immune-mediated Tissue Injury (LE079)

Dr James THOMPSON
Dr James THOMPSON
GLAXOSMITHKLINE, Stevenage, United Kingdom
Read more

Investigating the Chameleonic Properties of RGD Integrin Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis (LE090)


Organisers

Gold Sponsors

Silver Sponsors

Bronze Sponsors

Copyright 2022 LD Organisation srl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys